Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin and Aspalathin (SMA) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 19/June/2017, 10.36 pm